Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

LASIKA C SENEVIRATNE

Allopathic & Osteopathic Physicians Internal Medicine Hematology & Oncology

NPI
1437268174
CMS profile
156415
Location
LOS ANGELES, CA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2022 · Entire year

$12,970.67

188 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2022 · entire year · sorted by reported total

By paying entity

PY2022 · entire year · sorted by reported total

Page 4 of 4; records 151–188 of 188 matching records. This page contains 38 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

LASIKA C SENEVIRATNE

NPI 1437268174 · CMS profile ID 156415

Allopathic & Osteopathic Physicians / Internal Medicine / Hematology & Oncology

LOS ANGELES, CA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 4 of 4; records 151–188 of 188 matching records. This page contains 38 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1437268174?year=2022&recipient=provider&page=4#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
LASIKA C SENEVIRATNE, NPI 1437268174, CMS profile ID 156415. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 4 of 4; records 151–188 of 188 matching records. This page contains 38 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1437268174?year=2022&recipient=provider&page=4#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
APA 7
IndustryPayments. (2026). LASIKA C SENEVIRATNE, NPI 1437268174, CMS profile ID 156415. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 4 of 4; records 151–188 of 188 matching records. This page contains 38 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1437268174?year=2022&recipient=provider&page=4#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
Bluebook
LASIKA C SENEVIRATNE, NPI 1437268174, CMS profile ID 156415, IndustryPayments, General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 4 of 4; records 151–188 of 188 matching records. This page contains 38 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c. https://industrypayments.org/provider/npi-1437268174?year=2022&recipient=provider&page=4#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2022

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2022 · Physicians and non-physician practitioners · CMS publication 2026-06-30

188 matching records · $12,970.67 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 188 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 151–188 of 188.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
AstraZeneca Pharmaceuticals LP $24.5803/17/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 915795661 CMS
PUMA BIOTECHNOLOGY, INC. $21.5403/15/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 942295923 CMS
E.R. Squibb & Sons, L.L.C. $20.7403/14/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 932948071 CMS
Amgen Inc. $18.7103/08/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 939171065 CMS
Foundation Medicine, Inc. $120.7103/08/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 924046143 CMS
Seagen Inc. $21.7703/08/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 904115625 CMS
JAZZ PHARMACEUTICALS INC. $24.5403/03/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 951349873 CMS
G1 Therapeutics, Inc. $24.8002/23/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 954038463 CMS
AstraZeneca Pharmaceuticals LP $20.5802/17/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 914776059 CMS
PFIZER INC. $23.1402/17/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 949069699 CMS
Celgene Corporation $20.0802/16/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 932947939 CMS
Amgen Inc. $17.0702/15/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 939826011 CMS
Incyte Corporation $28.7502/14/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 943019633 CMS
EISAI INC. $21.9002/11/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 908056255 CMS
PUMA BIOTECHNOLOGY, INC. $20.0402/09/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 942294937 CMS
Bayer HealthCare Pharmaceuticals Inc. $15.2702/08/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 929808041 CMS
Kite Pharma, Inc. $25.4502/03/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 920061348 CMS
Takeda Pharmaceuticals U.S.A., Inc. $25.7402/02/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 955817955 CMS
E.R. Squibb & Sons, L.L.C. $1.0102/01/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 932948065 CMS
E.R. Squibb & Sons, L.L.C. $0.1602/01/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 932948067 CMS
E.R. Squibb & Sons, L.L.C. $18.0702/01/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 932948069 CMS
Celgene Corporation $2.6401/31/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 932947933 CMS
Celgene Corporation $0.4601/31/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 932947935 CMS
Celgene Corporation $10.8901/31/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 932947937 CMS
Celgene Corporation $5.0401/31/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 932948077 CMS
Celgene Corporation $3.3701/31/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 932948079 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $26.4901/27/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 887569431 CMS
Takeda Pharmaceuticals U.S.A., Inc. $23.3001/26/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 955817953 CMS
Karyopharm Therapeutics Inc. $31.4001/25/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 946522025 CMS
E.R. Squibb & Sons, L.L.C. $14.7501/21/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 932947931 CMS
Blueprint Medicines Corporation $28.7201/20/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 958934541 CMS
Celgene Corporation $1.3001/19/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 932947927 CMS
Celgene Corporation $21.2001/19/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 932947929 CMS
Myovant Sciences Inc. $26.4201/18/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 941240027 CMS
Amgen Inc. $26.2601/14/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 939171071 CMS
Genentech USA, Inc. $18.3101/11/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 950803437 CMS
Genentech USA, Inc. $15.7701/07/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 950805049 CMS
Seagen Inc. $28.4701/05/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 904115593 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $45,813.87 270
PY2020 $14,588.41 204
PY2021 $3,959.60 186
PY2022 $12,970.67 188
PY2023 $11,652.20 170
PY2024 $17,163.01 189
PY2025 $7,955.99 192

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $1,972,622.10 108
PY2024 Principal investigator $705,990.50 100
PY2023 Principal investigator $1,487,371.44 252
PY2022 Principal investigator $1,410,490.16 167
PY2021 Principal investigator $866,333.17 24
PY2020 Principal investigator $1,330,477.56 14
PY2019 Principal investigator $248,935.94 33

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

108 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 BeOne Medicines Ltd. $719.91 12/30/2025 Non-covered Recipient Entity
?Los Angeles Hematology/Oncology Medical Group Los Angeles Cancer Network Research
A Phase 3 Randomized, Open-Label Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma No dispute reported 06/30/2026 1190337084
Principal investigator 1 PUMA BIOTECHNOLOGY, INC. $554.93 12/29/2025 Non-covered Recipient Entity
LOS ANGELES CANCER NETWORK
ALI-1201 No dispute reported 06/30/2026 1251753400
Principal investigator 1 Genentech, Inc. $3,182.00 12/22/2025 Non-covered Recipient Entity
LOS ANGELES HEMATOLOGY ONCOLOGY MEDICAL GROUP LOS ANGELES CANCER NETWORK
Giredestrant CDKi of Choice in ESR1m Enriched 1L HR mBC Secondary Endocrine Resistant Patients No dispute reported 06/30/2026 1211621371
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $11,737.82 12/17/2025 Non-covered Recipient Entity
THE ONEONCOLOGY RESEARCH NETWORK
A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer No dispute reported 06/30/2026 1233745024
Principal investigator 1 Novartis Pharmaceuticals Corporation $210,000.00 12/11/2025 Non-covered Recipient Entity
LOS ANGELES CANCER NETWORK
Patient Journey, Treatment Patterns, and Clinical Outcomes of Women Diagnosed With HR+/HER2 Early-Stage Breast Cancer No dispute reported 06/30/2026 1190307471
Principal investigator 1 BeOne Medicines Ltd. $4,576.00 12/09/2025 Non-covered Recipient Entity
?Los Angeles Hematology/Oncology Medical Group Los Angeles Cancer Network Research
A Phase 3 Randomized, Open-Label Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma No dispute reported 06/30/2026 1190334464
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $750.00 12/05/2025 Non-covered Recipient Entity
THE ONEONCOLOGY RESEARCH NETWORK
A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer No dispute reported 06/30/2026 1233745026
Principal investigator 1 Genentech, Inc. $122.00 12/01/2025 Non-covered Recipient Entity
LOS ANGELES HEMATOLOGY ONCOLOGY MEDICAL GROUP LOS ANGELES CANCER NETWORK
Giredestrant CDKi of Choice in ESR1m Enriched 1L HR mBC Secondary Endocrine Resistant Patients No dispute reported 06/30/2026 1211621367
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $50,909.80 11/26/2025 Non-covered Recipient Entity
Los Angeles Hematology Oncology Medical Group
A PHASE 3, TWO-STAGE, RANDOMIZED, MULTICENTER, OPEN-LABEL STUDY COMPARING CC-92480 (BMS-986348), CARFILZOMIB AND DEXAMETHASONE (480Kd) VERSUS CARFILZOMIB AND DEXAMETHASONE (Kd) IN PARTICIPANTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA (RRMM). No dispute reported 06/30/2026 1235996165
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $750.00 11/14/2025 Non-covered Recipient Entity
THE ONEONCOLOGY RESEARCH NETWORK
A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer No dispute reported 06/30/2026 1233745022
Principal investigator 1 BeOne Medicines Ltd. $62,880.00 11/12/2025 Non-covered Recipient Entity
?Los Angeles Hematology/Oncology Medical Group Los Angeles Cancer Network Research
A Phase 3 Randomized, Open-Label Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma No dispute reported 06/30/2026 1190330167
Principal investigator 1 BeOne Medicines Ltd. $719.91 11/12/2025 Non-covered Recipient Entity
?Los Angeles Hematology/Oncology Medical Group Los Angeles Cancer Network Research
A Phase 3 Randomized, Open-Label Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma No dispute reported 06/30/2026 1190330169
Principal investigator 1 BeOne Medicines Ltd. $6,740.00 11/12/2025 Non-covered Recipient Entity
?Los Angeles Hematology/Oncology Medical Group Los Angeles Cancer Network Research
A Phase 3 Randomized, Open-Label Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma No dispute reported 06/30/2026 1190334468
Principal investigator 1 Incyte Corporation $11,019.98 11/10/2025 Non-covered Recipient Entity
LOS ANGELES CANCER NETWORK
A phase 3, multicenter, randomized, double-blind, placebo-controlled trial comparing the efficacy and safety of tafasitamab plus lenalidomide in addition to R-CHOP versus R-CHOP in previously untreated, high-intermediate and high-risk patients with newly-diagnosed diffuse large B-cell lymphoma (DLBCL), Front Mind No dispute reported 06/30/2026 1240547947
Principal investigator 1 GlaxoSmithKline, LLC. $3,131.25 11/07/2025 Non-covered Recipient Entity
LOS ANGELES HEMATOLOGY ONCOLOGY MEDICAL GROUP
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER S No dispute reported 06/30/2026 1192103263
Principal investigator 1 Genentech, Inc. $1,000.00 10/29/2025 Non-covered Recipient Entity
LOS ANGELES HEMATOLOGY ONCOLOGY MEDICAL GROUP
Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC No dispute reported 06/30/2026 1211621318
Principal investigator 1 AstraZeneca UK Limited $5,539.10 10/17/2025 Non-covered Recipient Entity
LOS ANGELES HEMATOLOGY ONCOLOGY MEDICAL GROUP
A Phase III,Open label,Randomised,Multicentre Study of Ceralasertib Plus Durvalumab Versus Docetaxel in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer Without Actionable Genomic Alterations,and Whose Disease Has Progressed On or After Prior Anti PD 1 Therapy and Platinum based Chemotherapy LATIFY No dispute reported 06/30/2026 1185544459
Principal investigator 1 PUMA BIOTECHNOLOGY, INC. $3,780.00 10/15/2025 Non-covered Recipient Entity
LOS ANGELES CANCER NETWORK
ALI-1201 No dispute reported 06/30/2026 1251753402
Principal investigator 1 PUMA BIOTECHNOLOGY, INC. $34,007.85 10/15/2025 Non-covered Recipient Entity
LOS ANGELES CANCER NETWORK
ALI-1201 No dispute reported 06/30/2026 1251753406
Principal investigator 1 Genentech, Inc. $7,891.00 10/14/2025 Non-covered Recipient Entity
LOS ANGELES HEMATOLOGY ONCOLOGY MEDICAL GROUP LOS ANGELES CANCER NETWORK
GIREDESTRANT in 1L HER2 ER mBC patients No dispute reported 06/30/2026 1211621359
Principal investigator 1 Genentech, Inc. $10,187.00 10/08/2025 Non-covered Recipient Entity
LOS ANGELES HEMATOLOGY ONCOLOGY MEDICAL GROUP LOS ANGELES CANCER NETWORK
Phase III study to compare inavolisib plus fulvestrant versus alpelisib plus fulvestrant in mBC No dispute reported 06/30/2026 1211621337
Principal investigator 1 PFIZER INC. $22,750.00 10/08/2025 Non-covered Recipient Entity
Los Angeles Hematology Oncology Medical Group
AN INTERVENTIONAL OPENLABEL RANDOMIZED MULTICENTER PHASE 3 STUDY OF PF07248144 PLUS FULVESTRANT COMPARED TO INVESTIGATORS CHOICE OF THERAPY IN ADULT PARTICIPANTS WITH HORMONE RECEPTORPOSITIVE HER2NEGATIVE ADVANCEDMETASTATIC BREAST CANCER WHOSE DISEASE PROGRESSED AFTER PRIOR CDK46 INHIBITORBASED THERAPY No dispute reported 06/30/2026 1228740912
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $1,000.00 10/01/2025 Non-covered Recipient Entity
THE ONEONCOLOGY RESEARCH NETWORK
A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer No dispute reported 06/30/2026 1233745018
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $750.00 10/01/2025 Non-covered Recipient Entity
THE ONEONCOLOGY RESEARCH NETWORK
A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer No dispute reported 06/30/2026 1233745020
Principal investigator 1 BeOne Medicines Ltd. $10,610.00 09/30/2025 Non-covered Recipient Entity
?Los Angeles Hematology/Oncology Medical Group Los Angeles Cancer Network Research
A Phase 3 Randomized, Open-Label Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma No dispute reported 06/30/2026 1190334458
Principal investigator 1 BeOne Medicines Ltd. $62,880.00 09/29/2025 Non-covered Recipient Entity
?Los Angeles Hematology/Oncology Medical Group Los Angeles Cancer Network Research
A Phase 3 Randomized, Open-Label Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma No dispute reported 06/30/2026 1190336876
Principal investigator 1 Genentech, Inc. $23,320.00 09/24/2025 Non-covered Recipient Entity
LOS ANGELES HEMATOLOGY ONCOLOGY MEDICAL GROUP LOS ANGELES CANCER NETWORK
Giredestrant CDKi of Choice in ESR1m Enriched 1L HR mBC Secondary Endocrine Resistant Patients No dispute reported 06/30/2026 1211621363
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $13,800.00 09/19/2025 Non-covered Recipient Entity
THE ONEONCOLOGY RESEARCH NETWORK
A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer No dispute reported 06/30/2026 1233745016
Principal investigator 1 Genentech, Inc. $11,469.00 09/17/2025 Non-covered Recipient Entity
LOS ANGELES HEMATOLOGY ONCOLOGY MEDICAL GROUP LOS ANGELES CANCER NETWORK
Phase III study to compare inavolisib plus fulvestrant versus alpelisib plus fulvestrant in mBC No dispute reported 06/30/2026 1211621334
Principal investigator 1 PFIZER INC. $24,270.00 09/09/2025 Non-covered Recipient Entity
LOS ANGELES HEMATOLOGY ONCOLOGY MED
A PHASE 1B2 OPENLABEL MULTICOHORT STUDY OF DISITAMAB VEDOTIN IN ADULTS WITH HER2 EXPRESSING ADVANCED BREAST CANCER No dispute reported 06/30/2026 1228757601
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $750.00 09/05/2025 Non-covered Recipient Entity
THE ONEONCOLOGY RESEARCH NETWORK
A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer No dispute reported 06/30/2026 1233745014
Principal investigator 1 BeOne Medicines Ltd. $31,440.00 09/03/2025 Non-covered Recipient Entity
?Los Angeles Hematology/Oncology Medical Group Los Angeles Cancer Network Research
A Phase 3 Randomized, Open-Label Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma No dispute reported 06/30/2026 1190330145
Principal investigator 1 BeOne Medicines Ltd. $1,879.04 09/03/2025 Non-covered Recipient Entity
?Los Angeles Hematology/Oncology Medical Group Los Angeles Cancer Network Research
A Phase 3 Randomized, Open-Label Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma No dispute reported 06/30/2026 1190330147
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $26,000.00 08/29/2025 Non-covered Recipient Entity
Los Angeles Cancer Research
A Study of BMS-986315 and Nivolumab in Combination With Chemotherapy in Participants With First-line Stage IV or Recurrent Non-small Cell Lung Cancer (NSCLC) No dispute reported 06/30/2026 1235996171
Principal investigator 1 AstraZeneca Pharmaceuticals LP $43,746.10 08/27/2025 Non-covered Recipient Entity
THE ONEONCOLOGY RESEARCH NETWORK LLC
Capivasertib plus Palbociclib plus Fulvestrant for HR/HER2 Advanced Breast Cancer CAPItello 292. No dispute reported 06/30/2026 1185544461
Principal investigator 1 BeOne Medicines Ltd. $23,351.00 08/19/2025 Non-covered Recipient Entity
?Los Angeles Hematology/Oncology Medical Group Los Angeles Cancer Network Research
A Phase 3 Randomized, Open-Label Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma No dispute reported 06/30/2026 1190334450
Principal investigator 1 Genentech, Inc. $5,985.00 08/15/2025 Non-covered Recipient Entity
LOS ANGELES HEMATOLOGY ONCOLOGY MEDICAL GROUP LOS ANGELES CANCER NETWORK
GIREDESTRANT in 1L HER2 ER mBC patients No dispute reported 06/30/2026 1211621354
Principal investigator 1 PUMA BIOTECHNOLOGY, INC. $4,410.45 08/15/2025 Non-covered Recipient Entity
LOS ANGELES CANCER NETWORK
ALI-1201 No dispute reported 06/30/2026 1251753404
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $8,000.00 08/08/2025 Non-covered Recipient Entity
THE ONEONCOLOGY RESEARCH NETWORK
A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer No dispute reported 06/30/2026 1233745010
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $1,500.00 08/08/2025 Non-covered Recipient Entity
THE ONEONCOLOGY RESEARCH NETWORK
A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer No dispute reported 06/30/2026 1233745012
Principal investigator 1 BeOne Medicines Ltd. $62,880.00 08/05/2025 Non-covered Recipient Entity
?Los Angeles Hematology/Oncology Medical Group Los Angeles Cancer Network Research
A Phase 3 Randomized, Open-Label Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma No dispute reported 06/30/2026 1190336941
Principal investigator 1 BeOne Medicines Ltd. $1,879.04 08/05/2025 Non-covered Recipient Entity
?Los Angeles Hematology/Oncology Medical Group Los Angeles Cancer Network Research
A Phase 3 Randomized, Open-Label Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma No dispute reported 06/30/2026 1190336945
Principal investigator 1 BeOne Medicines Ltd. $37,564.99 07/22/2025 Non-covered Recipient Entity
?Los Angeles Hematology/Oncology Medical Group Los Angeles Cancer Network Research
A Phase 3 Randomized, Open-Label Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma No dispute reported 06/30/2026 1190334454
Principal investigator 1 BeOne Medicines Ltd. $2,600.00 07/15/2025 Non-covered Recipient Entity
?Los Angeles Hematology/Oncology Medical Group Los Angeles Cancer Network Research
A Phase 3 Randomized, Open-Label Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma No dispute reported 06/30/2026 1190328053
Principal investigator 1 BeOne Medicines Ltd. $3,758.08 06/27/2025 Non-covered Recipient Entity
?Los Angeles Hematology/Oncology Medical Group Los Angeles Cancer Network Research
A Phase 3 Randomized, Open-Label Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma No dispute reported 06/30/2026 1190336992
Principal investigator 1 BeOne Medicines Ltd. $9,395.20 06/27/2025 Non-covered Recipient Entity
?Los Angeles Hematology/Oncology Medical Group Los Angeles Cancer Network Research
A Phase 3 Randomized, Open-Label Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma No dispute reported 06/30/2026 1190336997
Principal investigator 1 BeOne Medicines Ltd. $15,720.00 06/20/2025 Non-covered Recipient Entity
?Los Angeles Hematology/Oncology Medical Group Los Angeles Cancer Network Research
A Phase 3 Randomized, Open-Label Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma No dispute reported 06/30/2026 1190330149
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $2,104.10 06/12/2025 Non-covered Recipient Entity
LOS ANGELES HEMATOLOGY ONCOLOGY MEDICAL GROUP
A PHASE 1/2 OPEN-LABEL STUDY TO INVESTIGATE THE SAFETY AND TOLERABILITY, EFFICACY, PHARMACOKINETICS, AND IMMUNOGENICITY OF TAK-573 AS A SINGLE AGENT IN PATIENTS WITH REFRACTORY MULTIPLE MYELOMA No dispute reported 06/30/2026 1223281162
Principal investigator 1 Genentech, Inc. $12,575.00 06/11/2025 Non-covered Recipient Entity
LOS ANGELES HEMATOLOGY ONCOLOGY MEDICAL GROUP LOS ANGELES CANCER NETWORK
Phase III study to compare inavolisib plus fulvestrant versus alpelisib plus fulvestrant in mBC No dispute reported 06/30/2026 1211621321
Principal investigator 1 BeOne Medicines Ltd. $62,880.00 06/10/2025 Non-covered Recipient Entity
?Los Angeles Hematology/Oncology Medical Group Los Angeles Cancer Network Research
A Phase 3 Randomized, Open-Label Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma No dispute reported 06/30/2026 1190337053
Principal investigator 1 BeOne Medicines Ltd. $1,879.04 06/10/2025 Non-covered Recipient Entity
?Los Angeles Hematology/Oncology Medical Group Los Angeles Cancer Network Research
A Phase 3 Randomized, Open-Label Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma No dispute reported 06/30/2026 1190337058
Principal investigator 1 Genentech, Inc. $4,078.00 05/23/2025 Non-covered Recipient Entity
LOS ANGELES HEMATOLOGY ONCOLOGY MEDICAL GROUP LOS ANGELES CANCER NETWORK
GIREDESTRANT in 1L HER2 ER mBC patients No dispute reported 06/30/2026 1211621341
Principal investigator 1 BeiGene, Ltd. $15,720.00 05/21/2025 Non-covered Recipient Entity
?Los Angeles Hematology/Oncology Medical Group Los Angeles Cancer Network Research
A Phase 3 Randomized, Open-Label Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma No dispute reported 06/30/2026 1190323502
Principal investigator 1 BeiGene, Ltd. $17,188.99 05/20/2025 Non-covered Recipient Entity
?Los Angeles Hematology/Oncology Medical Group Los Angeles Cancer Network Research
A Phase 3 Randomized, Open-Label Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma No dispute reported 06/30/2026 1190320424
Principal investigator 1 BeiGene, Ltd. $15,720.00 05/08/2025 Non-covered Recipient Entity
?Los Angeles Hematology/Oncology Medical Group Los Angeles Cancer Network Research
A Phase 3 Randomized, Open-Label Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma No dispute reported 06/30/2026 1190323564
Principal investigator 1 BeiGene, Ltd. $1,439.81 05/08/2025 Non-covered Recipient Entity
?Los Angeles Hematology/Oncology Medical Group Los Angeles Cancer Network Research
A Phase 3 Randomized, Open-Label Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma No dispute reported 06/30/2026 1190323566
Principal investigator 1 BeiGene, Ltd. $4,697.60 05/08/2025 Non-covered Recipient Entity
?Los Angeles Hematology/Oncology Medical Group Los Angeles Cancer Network Research
A Phase 3 Randomized, Open-Label Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma No dispute reported 06/30/2026 1190323568
Principal investigator 1 BeiGene, Ltd. $12,467.00 04/29/2025 Non-covered Recipient Entity
?Los Angeles Hematology/Oncology Medical Group Los Angeles Cancer Network Research
A Phase 3 Randomized, Open-Label Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma No dispute reported 06/30/2026 1190320902
Principal investigator 1 GlaxoSmithKline, LLC. $797.62 04/28/2025 Non-covered Recipient Entity
LOS ANGELES HEMATOLOGY ONCOLOGY MEDICAL GROUP
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER S No dispute reported 06/30/2026 1192103244
Principal investigator 1 GlaxoSmithKline, LLC. $797.62 04/28/2025 Non-covered Recipient Entity
LOS ANGELES HEMATOLOGY ONCOLOGY MEDICAL GROUP
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER S No dispute reported 06/30/2026 1192103252
Principal investigator 1 GlaxoSmithKline, LLC. $5,469.75 04/28/2025 Non-covered Recipient Entity
LOS ANGELES HEMATOLOGY ONCOLOGY MEDICAL GROUP
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER S No dispute reported 06/30/2026 1192103258
Principal investigator 1 GlaxoSmithKline, LLC. $797.62 04/28/2025 Non-covered Recipient Entity
LOS ANGELES HEMATOLOGY ONCOLOGY MEDICAL GROUP
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER S No dispute reported 06/30/2026 1192104651
Principal investigator 1 GlaxoSmithKline, LLC. $797.62 04/28/2025 Non-covered Recipient Entity
LOS ANGELES HEMATOLOGY ONCOLOGY MEDICAL GROUP
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER S No dispute reported 06/30/2026 1192104657
Principal investigator 1 GlaxoSmithKline, LLC. $797.62 04/28/2025 Non-covered Recipient Entity
LOS ANGELES HEMATOLOGY ONCOLOGY MEDICAL GROUP
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER S No dispute reported 06/30/2026 1192104663
Principal investigator 1 GlaxoSmithKline, LLC. $1,298.25 04/28/2025 Non-covered Recipient Entity
LOS ANGELES HEMATOLOGY ONCOLOGY MEDICAL GROUP
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER S No dispute reported 06/30/2026 1192104669
Principal investigator 1 BeiGene, Ltd. $62,880.00 04/25/2025 Non-covered Recipient Entity
?Los Angeles Hematology/Oncology Medical Group Los Angeles Cancer Network Research
A Phase 3 Randomized, Open-Label Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma No dispute reported 06/30/2026 1190325232
Principal investigator 1 BeiGene, Ltd. $17,225.44 04/22/2025 Non-covered Recipient Entity
?Los Angeles Hematology/Oncology Medical Group Los Angeles Cancer Network Research
A Phase 3 Randomized, Open-Label Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma No dispute reported 06/30/2026 1190321862
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $16.36 04/21/2025 Non-covered Recipient Entity
Los Angeles Hematology Oncology
A PHASE 3, TWO-STAGE, RANDOMIZED, MULTICENTER, OPEN-LABEL STUDY COMPARING CC-92480 (BMS-986348), CARFILZOMIB AND DEXAMETHASONE (480Kd) VERSUS CARFILZOMIB AND DEXAMETHASONE (Kd) IN PARTICIPANTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA (RRMM). No dispute reported 06/30/2026 1235996169
Principal investigator 1 Novartis Pharmaceuticals Corporation $22,618.47 04/16/2025 Non-covered Recipient Entity
SOUTHERN CA ONCOLOGY RESEARCH ALLIANCE
Ribociclib Standard Endocrine therapy in patients with HR HER2 Early BC at High amp Intermediate Risk for Recurrence No dispute reported 06/30/2026 1190308354
Principal investigator 1 Genentech, Inc. $3,873.00 04/15/2025 Non-covered Recipient Entity
LOS ANGELES HEMATOLOGY ONCOLOGY MEDICAL GROUP LOS ANGELES CANCER NETWORK
GIREDESTRANT in 1L HER2 ER mBC patients No dispute reported 06/30/2026 1211621349
Principal investigator 1 BeiGene, Ltd. $17,973.99 04/08/2025 Non-covered Recipient Entity
?Los Angeles Hematology/Oncology Medical Group Los Angeles Cancer Network Research
A Phase 3 Randomized, Open-Label Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma No dispute reported 06/30/2026 1190320422
Principal investigator 1 AstraZeneca UK Limited $119,808.30 04/02/2025 Non-covered Recipient Entity
LOS ANGELES HEMATOLOGY ONCOLOGY MEDICAL GROUP
CAMBRIA-2 A Phase III, Open-Label, Randomised Study to Assess the Efficacy and Safety of Camizestrant (AZD9833, a Next Generation, Oral Selective Estrogen Receptor Degrader) vs Standard Endocrine Therapy (Aromatase Inhibitor or Tamoxifen) as Adjuvant Treatment for Patients With ER+/HER2- Early Breast Cancer and an Intermediate-high or High risk of Recurrence Who Have Completed Definitive Locoregional Treatment and Have No Evidence of Disease No dispute reported 06/30/2026 1185544455
Principal investigator 1 BeiGene, Ltd. $25,838.16 03/31/2025 Non-covered Recipient Entity
?Los Angeles Hematology/Oncology Medical Group Los Angeles Cancer Network Research
A Phase 3 Randomized, Open-Label Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma No dispute reported 06/30/2026 1190321892
Principal investigator 1 BeiGene, Ltd. $15,720.00 03/28/2025 Non-covered Recipient Entity
?Los Angeles Hematology/Oncology Medical Group Los Angeles Cancer Network Research
A Phase 3 Randomized, Open-Label Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma No dispute reported 06/30/2026 1190321964
Principal investigator 1 BeiGene, Ltd. $1,439.81 03/28/2025 Non-covered Recipient Entity
?Los Angeles Hematology/Oncology Medical Group Los Angeles Cancer Network Research
A Phase 3 Randomized, Open-Label Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma No dispute reported 06/30/2026 1190321966
Principal investigator 1 BeiGene, Ltd. $8,612.72 03/28/2025 Non-covered Recipient Entity
?Los Angeles Hematology/Oncology Medical Group Los Angeles Cancer Network Research
A Phase 3 Randomized, Open-Label Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma No dispute reported 06/30/2026 1190321968
Principal investigator 1 BeiGene, Ltd. $1,879.04 03/28/2025 Non-covered Recipient Entity
?Los Angeles Hematology/Oncology Medical Group Los Angeles Cancer Network Research
A Phase 3 Randomized, Open-Label Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma No dispute reported 06/30/2026 1190321970
Principal investigator 1 BeiGene, Ltd. $4,697.60 03/28/2025 Non-covered Recipient Entity
?Los Angeles Hematology/Oncology Medical Group Los Angeles Cancer Network Research
A Phase 3 Randomized, Open-Label Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma No dispute reported 06/30/2026 1190321972
Principal investigator 1 BeiGene, Ltd. $11,302.00 03/25/2025 Non-covered Recipient Entity
?Los Angeles Hematology/Oncology Medical Group Los Angeles Cancer Network Research
A Phase 3 Randomized, Open-Label Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma No dispute reported 06/30/2026 1190320418
Principal investigator 1 BeiGene, Ltd. $31,440.00 03/19/2025 Non-covered Recipient Entity
?Los Angeles Hematology/Oncology Medical Group Los Angeles Cancer Network Research
A Phase 3 Randomized, Open-Label Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma No dispute reported 06/30/2026 1190321912
Principal investigator 1 BeiGene, Ltd. $25,838.16 03/19/2025 Non-covered Recipient Entity
?Los Angeles Hematology/Oncology Medical Group Los Angeles Cancer Network Research
A Phase 3 Randomized, Open-Label Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma No dispute reported 06/30/2026 1190321914
Principal investigator 1 BeiGene, Ltd. $4,319.43 03/03/2025 Non-covered Recipient Entity
?Los Angeles Hematology/Oncology Medical Group Los Angeles Cancer Network Research
A Phase 3 Randomized, Open-Label Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma No dispute reported 06/30/2026 1190325258
Principal investigator 1 BeiGene, Ltd. $8,612.72 03/03/2025 Non-covered Recipient Entity
?Los Angeles Hematology/Oncology Medical Group Los Angeles Cancer Network Research
A Phase 3 Randomized, Open-Label Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma No dispute reported 06/30/2026 1190325260
Principal investigator 1 BeiGene, Ltd. $1,879.04 03/03/2025 Non-covered Recipient Entity
?Los Angeles Hematology/Oncology Medical Group Los Angeles Cancer Network Research
A Phase 3 Randomized, Open-Label Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma No dispute reported 06/30/2026 1190325262
Principal investigator 1 BeiGene, Ltd. $4,697.60 03/03/2025 Non-covered Recipient Entity
?Los Angeles Hematology/Oncology Medical Group Los Angeles Cancer Network Research
A Phase 3 Randomized, Open-Label Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma No dispute reported 06/30/2026 1190325274
Principal investigator 1 BeiGene, Ltd. $15,720.00 03/03/2025 Non-covered Recipient Entity
?Los Angeles Hematology/Oncology Medical Group Los Angeles Cancer Network Research
A Phase 3 Randomized, Open-Label Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma No dispute reported 06/30/2026 1190325276
Principal investigator 1 AstraZeneca Pharmaceuticals LP $33,083.22 02/28/2025 Non-covered Recipient Entity
LOS ANGELES HEMATOLOGY ONCOLOGY MEDICAL GROUP
A Phase 3 Open-label Trial of Neoadjuvant Trastuzumab Deruxtecan (T-DXd) Monotherapy or T-DXd followed by THP Compared to ddAC-THP in Participants with High-risk HER2-positive Early-stage Breast Cancer (DESTINY-Breast11) No dispute reported 06/30/2026 1185544463
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $24,046.14 02/25/2025 Non-covered Recipient Entity
Los Angeles Hematology Oncology
A PHASE 3, TWO-STAGE, RANDOMIZED, MULTICENTER, OPEN-LABEL STUDY COMPARING CC-92480 (BMS-986348), CARFILZOMIB AND DEXAMETHASONE (480Kd) VERSUS CARFILZOMIB AND DEXAMETHASONE (Kd) IN PARTICIPANTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA (RRMM). No dispute reported 06/30/2026 1235996167
Principal investigator 1 BeiGene, Ltd. $15,720.00 02/19/2025 Non-covered Recipient Entity
?Los Angeles Hematology/Oncology Medical Group Los Angeles Cancer Network Research
A Phase 3 Randomized, Open-Label Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma No dispute reported 06/30/2026 1190321934
Principal investigator 1 BeiGene, Ltd. $4,319.43 02/19/2025 Non-covered Recipient Entity
?Los Angeles Hematology/Oncology Medical Group Los Angeles Cancer Network Research
A Phase 3 Randomized, Open-Label Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma No dispute reported 06/30/2026 1190321936
Principal investigator 1 BeiGene, Ltd. $8,612.72 02/19/2025 Non-covered Recipient Entity
?Los Angeles Hematology/Oncology Medical Group Los Angeles Cancer Network Research
A Phase 3 Randomized, Open-Label Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma No dispute reported 06/30/2026 1190321938
Principal investigator 1 BeiGene, Ltd. $1,879.04 02/19/2025 Non-covered Recipient Entity
?Los Angeles Hematology/Oncology Medical Group Los Angeles Cancer Network Research
A Phase 3 Randomized, Open-Label Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma No dispute reported 06/30/2026 1190323530
Principal investigator 1 BeiGene, Ltd. $4,697.60 02/19/2025 Non-covered Recipient Entity
?Los Angeles Hematology/Oncology Medical Group Los Angeles Cancer Network Research
A Phase 3 Randomized, Open-Label Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma No dispute reported 06/30/2026 1190323532
Principal investigator 1 Genentech, Inc. $1,800.00 02/19/2025 Non-covered Recipient Entity
LOS ANGELES HEMATOLOGY ONCOLOGY MEDICAL GROUP LOS ANGELES CANCER NETWORK
Phase III study to compare inavolisib plus fulvestrant versus alpelisib plus fulvestrant in mBC No dispute reported 06/30/2026 1211621325
Principal investigator 1 BeiGene, Ltd. $15,720.00 02/11/2025 Non-covered Recipient Entity
?Los Angeles Hematology/Oncology Medical Group Los Angeles Cancer Network Research
A Phase 3 Randomized, Open-Label Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma No dispute reported 06/30/2026 1190322024
Principal investigator 1 BeiGene, Ltd. $1,439.81 02/11/2025 Non-covered Recipient Entity
?Los Angeles Hematology/Oncology Medical Group Los Angeles Cancer Network Research
A Phase 3 Randomized, Open-Label Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma No dispute reported 06/30/2026 1190322026
Principal investigator 1 BeiGene, Ltd. $8,612.72 02/11/2025 Non-covered Recipient Entity
?Los Angeles Hematology/Oncology Medical Group Los Angeles Cancer Network Research
A Phase 3 Randomized, Open-Label Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma No dispute reported 06/30/2026 1190322028
Principal investigator 1 Genentech, Inc. $5,028.00 02/05/2025 Non-covered Recipient Entity
LOS ANGELES HEMATOLOGY ONCOLOGY MEDICAL GROUP
Phase III study of giredestrant everolimus vs everolimus exemestane in ER HER2 locally adv or mBC No dispute reported 06/30/2026 1211621311
Principal investigator 1 AstraZeneca Pharmaceuticals LP $34,147.59 01/29/2025 Non-covered Recipient Entity
THE ONEONCOLOGY RESEARCH NETWORK LLC
Phase III Study of Trastuzumab Deruxtecan (T-DXd) with or without Pertuzumab versus Taxane Trastuzumab and Pertuzumab in HER2-positive First-line Metastatic Breast Cancer (DESTINY-Breast09) No dispute reported 06/30/2026 1185544467
Principal investigator 1 BeiGene, Ltd. $4,774.00 01/28/2025 Non-covered Recipient Entity
?Los Angeles Hematology/Oncology Medical Group Los Angeles Cancer Network Research
A Phase 3 Randomized, Open-Label Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma No dispute reported 06/30/2026 1190320420
Principal investigator 1 Celgene Corporation $164,778.40 01/27/2025 Non-covered Recipient Entity
Los Angeles Hematology Oncology Medical Group
A PHASE 3, TWO-STAGE, RANDOMIZED, MULTICENTER, OPEN-LABEL STUDY COMPARING CC-92480 (BMS-986348), CARFILZOMIB AND DEXAMETHASONE (480Kd) VERSUS CARFILZOMIB AND DEXAMETHASONE (Kd) IN PARTICIPANTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA (RRMM). No dispute reported 06/30/2026 1222307189
Principal investigator 1 Genentech, Inc. $26,064.00 01/22/2025 Non-covered Recipient Entity
LOS ANGELES HEMATOLOGY ONCOLOGY MEDICAL GROUP LOS ANGELES CANCER NETWORK
Phase III study to compare inavolisib plus fulvestrant versus alpelisib plus fulvestrant in mBC No dispute reported 06/30/2026 1211621329
Principal investigator 1 Genentech, Inc. $830.00 01/17/2025 Non-covered Recipient Entity
LOS ANGELES HEMATOLOGY ONCOLOGY MEDICAL GROUP LOS ANGELES CANCER NETWORK
GIREDESTRANT in 1L HER2 ER mBC patients No dispute reported 06/30/2026 1211621345
Principal investigator 1 AstraZeneca Pharmaceuticals LP $7,500.20 01/15/2025 Non-covered Recipient Entity
LOS ANGELES HEMATOLOGY ONCOLOGY MEDICAL GROUP
A Phase 3 Open-label Randomised Study of Datopotamab Deruxtecan (Dato DXd) Versus Investigators Choice of Chemotherapy in Patients who are not Candidates for PD 1/PD L1 Inhibitor Therapy in First-line Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer No dispute reported 06/30/2026 1185544465
Principal investigator 1 BeiGene, Ltd. $1,439.81 01/14/2025 Non-covered Recipient Entity
?Los Angeles Hematology/Oncology Medical Group Los Angeles Cancer Network Research
A Phase 3 Randomized, Open-Label Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma No dispute reported 06/30/2026 1190325330
Principal investigator 1 Incyte Corporation $118.76 01/14/2025 Non-covered Recipient Entity
LOS ANGELES HEMATOLOGY ONCOLOGY MEDICAL GROUP
A phase 3, multicenter, randomized, double-blind, placebo-controlled trial comparing the efficacy and safety of tafasitamab plus lenalidomide in addition to R-CHOP versus R-CHOP in previously untreated, high-intermediate and high-risk patients with newly-diagnosed diffuse large B-cell lymphoma (DLBCL), Front Mind No dispute reported 06/30/2026 1240547958
Principal investigator 1 AstraZeneca Pharmaceuticals LP $17,676.88 01/03/2025 Non-covered Recipient Entity
LOS ANGELES HEMATOLOGY ONCOLOGY MEDICAL GROUP
A Phase 3 Open-label, Randomised Study of Datopotamab Deruxtecan?(DatoDXd) With or Without Durvalumab Versus Investigators Choice of Therapy in Patients With Stage I-III Triple-negative Breast Cancer Who Have Residual Invasive Disease in the Breast and/or Axillary Lymph Nodes at Surgical Resection Following Neoadjuvant Systemic Therapy No dispute reported 06/30/2026 1185544457
Principal investigator 1 AstraZeneca Pharmaceuticals LP $140,529.85 01/03/2025 Non-covered Recipient Entity
LOS ANGELES HEMATOLOGY ONCOLOGY MEDICAL GROUP
A Phase III, Randomised, Open-label, Multicentre, Global Study of Datopotamab Deruxtecan (Dato-DXd) in Combination with Durvalumab and Carboplatin Versus Pembrolizumab in Combination with Platinum-based Chemotherapy for the First-line Treatment of Patients with Locally Advanced or Metastatic NSCLC without Actionable Genomic Alterations (D926NC00001; AVANZAR) No dispute reported 06/30/2026 1185544469